Literature DB >> 9600824

Prognostic factors of primary adenocarcinoma of the uterine cervix.

R J Chen1, D Y Chang, M L Yen, E F Lee, S C Huang, S N Chow, C Y Hsieh.   

Abstract

OBJECTIVE: To determine which clinicopathological factors influence the prognosis of cervical adenocarcinoma.
METHODS: Three hundred and two cases of primary adenocarcinoma of the uterine cervix, treated between 1977 and 1994, were studied retrospectively. Clinical data and pathological findings with respect to primary therapy were reviewed and evaluated.
RESULTS: The 5-year survival rates for stages I, II, and III/IV were 75.9, 62.9, and 25.1%, respectively. International Federation of Gynecology and Obstetrics stage (P < 0. 0001), cell type (P = 0.0176), tumor grade (P = 0.023), lymph node status (P = 0.018), and bulky tumor (P = 0.007) were found to be independent factors using the stepwise Cox proportional hazards model. Old age (P = 0.0581), presence of hypertension (P = 0.46), diabetes mellitus (P = 0.18), obesity (P = 0.15), and oral contraceptive use (P = 0.42) were not found to adversely influence survival rates for cervical adenocarcinoma after adjusting for other covariates. Adenosquamous adenocarcinoma had a better prognosis than endocervical columnar cell adenocarcinoma in stages I and II (P = 0. 0235). Also, in cervical adenocarcinoma's early stages, multivariate modeling revealed that chances of survival were significantly better for patients treated by radical surgery than for patients treated by radiation therapy (P < 0.001).
CONCLUSIONS: Survival rates for cervical adenocarcinoma were significantly influenced by stage, histologic subtype, tumor grade, the presence of a positive lymph node, and tumor size. Although a randomized prospective study is needed, our data imply that radical surgery may be considered a better primary modality of treatment than radiation therapy for the early stages of cervical adenocarcinoma. Further, the presence of hypertension, diabetes mellitus, or obesity may not adversely influence survival rates. Copyright 1998 Academic Press.

Entities:  

Mesh:

Year:  1998        PMID: 9600824     DOI: 10.1006/gyno.1998.4971

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy.

Authors:  Nora T Kizer; Premal H Thaker; Feng Gao; Israel Zighelboim; Matthew A Powell; Janet S Rader; David G Mutch; Perry W Grigsby
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

2.  Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.

Authors:  Yoshihisa Arakaki; Takuro Ariga; Joichi Heianna; Yuko Shimoji; Tadaharu Nakasone; Yusuke Taira; Tomoko Nakamoto; Takuma Ooyama; Wataru Kudaka; Itomi Kaneshima; Kumiko Nishihira; Keiko Mekaru; Yoichi Aoki
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 3.  Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix.

Authors:  Astrid Baalbergen; Yerney Veenstra; Lukas Stalpers
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

4.  Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.

Authors:  Eriko Yokoi; Seiji Mabuchi; Ryoko Takahashi; Yuri Matsumoto; Hiromasa Kuroda; Katsumi Kozasa; Tadashi Kimura
Journal:  J Gynecol Oncol       Date:  2016-12-08       Impact factor: 4.401

5.  Role of protease activated receptor-2 in lymph node metastasis of uterine cervical cancers.

Authors:  Israt Jahan; Jiro Fujimoto; Syed Mahfuzul Alam; Eriko Sato; Teruhiko Tamaya
Journal:  BMC Cancer       Date:  2008-10-20       Impact factor: 4.430

6.  Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers.

Authors:  J Fujimoto; H Toyoki; E Sato; H Sakaguchi; T Tamaya
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.